Need help finding what you are looking for?
Contact Us
PUBLISHER: Renub Research | PRODUCT CODE: 1484142
PUBLISHER: Renub Research | PRODUCT CODE: 1484142
Global Myocardial Infarction Market Report by Drug Class, Distribution Channels, Regions and Company Analysis 2024-2032
PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Global Myocardial Infarction Market share was valued at US$ 2.02 Billion in 2023. It is anticipated to increase at a CAGR of 6.06% from 2024 to 2032 and be valued at US$ 3.43 Billion by 2032.
A myocardium's part that receives little or no blood flow is what causes myocardial infarction (MI), also referred to as a "heart attack." An MI could be "silent" and go unnoticed, or it could be a catastrophic occurrence that results in hemodynamic decline and abrupt death. The underlying cause of the majority of myocardial infarctions is coronary artery disease. Oxygen is not available to the myocardium when coronary artery blockage occurs. Long-term oxygen supply deprivation of the heart can result in necrosis and death of heart cells. Patients may exhibit pressure or discomfort in the chest that radiates to the jaw, arm, shoulder, or neck. Myocardial ischemia may be linked to elevated biochemical markers such cardiac troponins and abnormalities in the electrocardiogram in addition to the history and physical examination.
Global Myocardial Infarction Market Growth Trends
- In 2023, there will be 8 billion people on Earth! Of these, 620 million or more people worldwide suffer from circulatory and cardiac ailments. The British Heart Foundation estimates that 60 million people worldwide suffer from a heart or circulation ailment each year.
- An estimated 1 in 13 persons worldwide suffer from a heart or circulatory ailment. About one in three fatalities worldwide are caused by heart and circulation disorders. According to the British Heart Foundation, there will be 20.5 million deaths in 2021, or 56,000 deaths every day, or one death every 1.5 seconds.
- The rise in cases of heart attack and cardiovascular diseases is propelling the global myocardial infarction market.
- Moreover, another major driver driving growth in the worldwide myocardial infarction market is the increasing incidence of certain associated risk factors, such as high cholesterol, excessive alcohol use, smoking, inactivity, etc.
- According to a CDC report, high blood pressure, high cholesterol, and smoking are the three main risk factors for heart disease that over half of all Americans (47%) have at least one of those.
- Various initiatives are taken to raise awareness regarding heart attacks. This adds to the growth of the global myocardial infarction industry.
- The Global Heart Hub's 2023 Heart Failure Awareness Month Campaign seeks to raise public awareness of heart failure. Our goal is to increase public knowledge of heart failure's warning signs, symptoms, and risk factors-as well as the value of prompt diagnosis and appropriate treatment. This year's campaign, with the hashtag #HighlightHeartFailure, aims to save lives by raising awareness of heart failure.
- The threefold goals of the World Heart Federation (WHF) are to promote information exchange, translate science into policy, and unite and guide the CVD community. With the tagline "Use Heart, Know Heart," World Heart Day 2023 provides a novel approach to spreading awareness by encouraging people to learn about their own cardiovascular health as well as the health of their friends, family, parents, and community.
United States Myocardial Infarction Market
- United Sates might hold a dominant position in the global myocardial infarction market. This is due to increase in product launches and approvals.
- In February 2024- Zydus Lifesciences Ltd. announced that the US health agency has given it final approval to produce and sell its generic Isosorbide Mononitrate extended-release tablets, which are intended to help patients with specific heart conditions avoid chest pain.
- In October 2023-Medinol declared that the FDA had approved its EluNIR-PERL drug-eluting stent (DES). Coronary heart disease is treated with this device.
- The growing number of people who are obese and the increase in incidences and prevalence of high rates of heart ailments are the main factors driving the myocardial infarction market expansion in this region.
- In 2022- states had an adult obesity rate at or over 35%, up from 19 states the year before, according to TFAH's analysis of the most recent data from the Behavioral Risk Factor Surveillance System of the Centers for Disease Control and Prevention (CDC). 10 years ago, not a single state had an adult obesity rate of 35% or more.
- 41.9 percent of adults in the country are obese. Adults who identify as Black or Latino had the greatest rates of obesity (44.9 percent and 45.6%, respectively).
- Cardiovascular disease (CVD) continues to be the top cause of mortality in the United States, accounting for 928,741 deaths in 2020, according to the American Heart Association.
- Coronary heart disease (CHD) accounted for 41.2% of all fatalities in the US in 2020 due to cardiovascular disease (CVD). Stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), heart failure (9.2%), and artery disorders (2.6%), round out the top five causes.
Global Myocardial Infarction Industry News
Pfizer, Sanofi-Aventis/Bristol-Myers Squibb, AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, Takeda, Novartis, Genentech, Amgen, Regeneron/Sanofi, Boehringer Ingelheim, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, and Mesoblast are the leading companies in the global myocardial infarction market.
- In March 2024 - The FDA authorized Novo Nordisk's weight-loss medication Wegovy in order to lower the risk of major cardiovascular problems in individuals with heart disease and obesity.
- In April 2024 - Johnson & Johnson will present clinical and real-world data from its cardiovascular portfolio at the 73rd Annual Scientific Session & Expo of the American College of Cardiology. Eleven abstracts, including five oral presentations, will be presented at the event. They will discuss the therapeutic advantages of novel medications, such XARELTO(R) (rivaroxaban), and innovative technologies, like those from Abiomed(R) and Biosense Webster(R), for the treatment of cardiovascular disorders.
- In November 2023 - Eli Lilly and Company's ZepboundTM (tirzepatide) injectable was approved by the U.S. Food and Drug Administration (FDA). This is the first and only obesity medication of its kind that stimulates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) hormone receptors.
- In June 2023 - The first anti-inflammatory medication for treating cardiovascular disease, colchicine, is approved by the FDA.
- In November 2022 - Johnson & Johnson has agreed to buy Abiomed, a supplier of cardiovascular solutions, for USD 16.6 Billion. Following the completion of the deal, Abiomed will function as a distinct business and enhance Johnson & Johnson MedTech's standing as a rising cardiovascular innovation. This will improve patient outcomes and raise the bar for treatment for heart failure, one of the deadliest illnesses.
Drug Class - Market breakup in 9 viewpoints:
1. Antiplatelet Agents
2. Glycoprotein IIb/IIIa Inhibitors
3. Antithrombotic Agents
4. Beta-adrenergic Blockers
5. Vasodilators
6. Angiotensin-converting Enzyme (ACE) Inhibitors
7. Angiotensin-receptor Blockers
8. Analgesics
9. Thrombolytics
Distribution Channel - Market breakup in 4 viewpoints:
1. Hospitals
2. Hospital Pharmacies
3. Drug Stores
4. Online Drug Stores
Countries - Market breakup of 25 Countries:
1. North America
- 1.1 United States
- 1.2 Canada
2. Europe
- 2.1 France
- 2.2 Germany
- 2.3 Italy
- 2.4 Spain
- 2.5 United Kingdom
- 2.6 Belgium
- 2.7 Netherlands
- 2.8 Turkey
3. Asia Pacific
- 3.1 China
- 3.2 Japan
- 3.3 India
- 3.4 South Korea
- 3.5 Thailand
- 3.6 Malaysia
- 3.7 Indonesia
- 3.8 Australia
- 3.9 New Zealand
4. Latin America
- 4.1 Brazil
- 4.2 Mexico
- 4.3 Argentina
5. Middle East & Africa
- 5.1 Saudi Arabia
- 5.2 UAE
- 5.3 South Africa
All the Key players have been covered from 3 Viewpoints:
- Overview
- Recent Development
- Revenue Analysis
Company Analysis:
1. Pfizer
2. Sanofi-Aventis/Bristol-Myers Squibb
3. AstraZeneca
4. Merck
5. Daiichi Sankyo
6. Eli Lilly and Company
7. Takeda
8. Novartis
9. Genentech
10. Amgen
11. Regeneron/Sanofi
12. Boehringer Ingelheim
13. Idorsia Pharmaceuticals
14. Faraday Pharmaceuticals
15. CSL Behring
16. Immediate Therapeutics
17. Mitsubishi Chemical Group
18. Kancera
19. Bayer
20. Recardio
21. Mesoblast
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
5. Exploring the Disease - Background and Key Insights
- 5.1 Introduction
- 5.2 Risk Factors
- 5.3 Pathophysiology
- 5.4 Diagnosis
- 5.5 Biomarkers
- 5.5.1 Biomarkers Originated from Myocardial Tissues
- 5.5.2 Biomarkers Induced by MI Incidence
- 5.5.3 Biomarkers Preexisted Before MI Occurred
- 5.6 Understanding Prior Myocardial Infarction - Definition and Overview
- 5.6.1 Recurrent MI
- 5.6.2 Reinfarction
- 5.6.3 Peri-procedural MI
- 5.7 Myocardial Infarction - WHO Criteria and Definition
- 5.7.1 Understanding MI in Category A: Definition and Diagnostic Standards
- 5.7.2 Category B definition and diagnostic criteria of MI if the requirements for diagnostic tests in Category A (above) Have Not Been Met
- 5.7.3 Understanding Probable MI in Category C: Definition and Diagnostic Standards
- 5.7.4 Fourth Universal Definition of Myocardial Infarction: Overview and Key Concepts
6. Comprehensive Treatment and Management
- 6.1 Antiplatelet agents
- 6.2 Anticoagulant agents
7. Practical Guidelines and Recommendations for Myocardial Infarction Care
- 7.1 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines: 2022
- 7.2 NICE Guidelines for Acute coronary syndromes: 2020
- 7.3 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation: 2017
- 7.4 Evidenced-based Recommendations from the Guidelines
- 7.5 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
8. Global Myocardial Infarction Market
9. Market Share - Global Myocardial Infarction Market
- 9.1 Drug Class
- 9.2 Distribution Channel
- 9.3 Country
10. Drug Class - Global Myocardial Infarction Market
- 10.1 Antiplatelet Agents
- 10.2 Glycoprotein IIb/IIIa Inhibitors
- 10.3 Antithrombotic Agents
- 10.4 Beta-adrenergic Blockers
- 10.5 Vasodilators
- 10.6 Angiotensin-converting Enzyme (ACE) Inhibitors
- 10.7 Angiotensin-receptor Blockers
- 10.8 Analgesics
- 10.9 Thrombolytics
11. Distribution Channel - Global Myocardial Infarction Market
- 11.1 Hospitals
- 11.2 Hospital Pharmacies
- 11.3 Drug Stores
- 11.4 Online Drug Stores
12. Country - Global Myocardial Infarction Market
- 12.1 North America
- 12.1.1 United States
- 12.1.2 Canada
- 12.2 Europe
- 12.2.1 France
- 12.2.2 Germany
- 12.2.3 Italy
- 12.2.4 Spain
- 12.2.5 United Kingdom
- 12.2.6 Belgium
- 12.2.7 Netherlands
- 12.2.8 Turkey
- 12.3 Asia Pacific
- 12.3.1 China
- 12.3.2 Japan
- 12.3.3 India
- 12.3.4 South Korea
- 12.3.5 Thailand
- 12.3.6 Malaysia
- 12.3.7 Indonesia
- 12.3.8 Australia
- 12.3.9 New Zealand
- 12.4 Latin America
- 12.4.1 Brazil
- 12.4.2 Mexico
- 12.4.3 Argentina
- 12.5 Middle East & Africa
- 12.5.1 Saudi Arabia
- 12.5.2 UAE
- 12.5.3 South Africa
13. Porter's Five Analysis - Global Myocardial Infarction Market
- 13.1 Bargaining Power of Buyers
- 13.2 Bargaining Power of Suppliers
- 13.3 Degree of Rivalry
- 13.4 Threat of New Entrants
- 13.5 Threat of Substitutes
14. SWOT Analysis - Global Myocardial Infarction Market
- 14.1 Strength
- 14.2 Weakness
- 14.3 Opportunity
- 14.4 Threat
15. Analysis of Marketed Therapies
- 15.1 Key Players
- 15.2 INSPRA (eplerenone): Pfizer
- 15.2.1 Description of Drug
- 15.2.2 Regulatory milestones
- 15.2.3 Safety and efficacy
- 15.3 PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb
- 15.3.1 Description of Drug
- 15.3.2 Regulatory milestones
- 15.3.3 Safety and efficacy
- 15.4 BRILINTA (ticagrelor): AstraZeneca
- 15.4.1 Description of Drug
- 15.4.2 Regulatory milestones
- 15.4.3 Safety and efficacy
- 15.5 ZONTIVITY (vorapaxar): Merck
- 15.5.1 Description of Drug
- 15.5.2 Regulatory milestones
- 15.5.3 Safety and efficacy
- 15.6 EFFIENT/EFIENT (prasugrel): Daiichi Sankyo/Eli Lilly and Company
- 15.6.1 Description of Drug
- 15.6.2 Regulatory milestones
- 15.6.3 Safety and efficacy
- 15.7 ATACAND (candesartan): AstraZeneca/Takeda
- 15.7.1 Description of Drug
- 15.7.2 Regulatory milestones
- 15.7.3 Safety and efficacy
- 15.8 DIOVAN (valsartan): Novartis
- 15.8.1 Description of Drug
- 15.8.2 Regulatory milestones
- 15.8.3 Safety and efficacy
- 15.9 TNKASE (tenecteplase): Genentech
- 15.9.1 Description of Drug
- 15.9.2 Regulatory milestones
- 15.9.3 Safety and efficacy
- 15.10 REPATHA (evolocumab): Amgen
- 15.10.1 Description of Drug
- 15.10.2 Regulatory milestones
- 15.10.3 Safety and efficacy
- 15.11 PRALUENT (alirocumab): Regeneron/Sanofi
- 15.11.1 Description of Drug
- 15.11.2 Regulatory milestones
- 15.11.3 Safety and efficacy
16. Analysis of Emerging Therapies
- 16.1 Key Players
- 16.2 FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
- 16.2.1 Description of Drug
- 16.2.2 Clinical Research & Development
- 16.2.3 Safety and efficacy
- 16.3 JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company
- 16.3.1 Description of Drug
- 16.3.2 Clinical Research & Development
- 16.3.3 Safety and efficacy
- 16.4 Pelacarsen (TQJ230): Novartis
- 16.4.1 Description of Drug
- 16.4.2 Clinical Research & Development
- 16.4.3 Safety and efficacy
- 16.5 Olpasiran: Amgen
- 16.5.1 Description of Drug
- 16.5.2 Clinical Research & Development
- 16.5.3 Safety and efficacy
- 16.6 Selatogrel: Idorsia Pharmaceuticals
- 16.6.1 Description of Drug
- 16.6.2 Clinical Research & Development
- 16.6.3 Safety and efficacy
- 16.7 FDY-5301: Faraday Pharmaceuticals
- 16.7.1 Description of Drug
- 16.7.2 Clinical Research & Development
- 16.7.3 Safety and efficacy
- 16.8 CSL112: CSL Behring
- 16.8.1 Description of Drug
- 16.8.2 Clinical Research & Development
- 16.8.3 Safety and efficacy
- 16.9 IMT-358: Immediate Therapeutics
- 16.9.1 Description of Drug
- 16.9.2 Clinical Research & Development
- 16.9.3 Safety and efficacy
- 16.10 CL2020: Mitsubishi Chemical Group
- 16.10.1 Description of Drug
- 16.10.2 Clinical Research & Development
- 16.10.3 Safety and efficacy
- 16.11 MEDI6570: AstraZeneca
- 16.11.1 Description of Drug
- 16.11.2 Clinical Research & Development
- 16.11.3 Safety and efficacy
- 16.12 KAND567: Kancera
- 16.12.1 Description of Drug
- 16.12.2 Clinical Research & Development
- 16.12.3 Safety and efficacy
- 16.13 Asundexian: Bayer
- 16.13.1 Description of Drug
- 16.13.2 Clinical Research & Development
- 16.13.3 Safety and efficacy
- 16.14 Dutogliptin: Recardio
- 16.14.1 Description of Drug
- 16.14.2 Clinical Research & Development
- 16.14.3 Safety and efficacy
- 16.15 MPC-25-IC: Mesoblast
- 16.15.1 Description of Drug
- 16.15.2 Clinical Research & Development
- 16.15.3 Safety and efficacy
17. Regulations and Reimbursement
- 17.1 PRALUENT (alirocumab)
- 17.2 INSPRA (eplerenone)
- 17.3 BRILINTA (ticagrelor)
- 17.4 REPATHA (evolocumab)
- 17.5 DIOVAN (valsartan)
- 17.6 ZONTIVITY (vorapaxar)
- 17.7 TNKase (tenecteplase)
- 17.8 Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)
List of Figures
- Figure-01: Global - Myocardial Infarction Market (Billion US$), 2019 - 2023
- Figure-02: Global - Forecast for Myocardial Infarction Market (Billion US$), 2024 - 2032
- Figure-03: Drug Class - Antiplatelet Agents Market (Million US$), 2019 - 2023
- Figure-04: Drug Class - Forecast for Antiplatelet Agents Market (Million US$), 2024 - 2032
- Figure-05: Drug Class - Glycoprotein IIb/IIIa Inhibitors Market (Million US$), 2019 - 2023
- Figure-06: Drug Class - Forecast for Glycoprotein IIb/IIIa Inhibitors Market (Million US$), 2024 - 2032
- Figure-07: Drug Class - Antithrombotic Agents Market (Million US$), 2019 - 2023
- Figure-08: Drug Class - Forecast for Antithrombotic Agents Market (Million US$), 2024 - 2032
- Figure-09: Drug Class - Beta-adrenergic Blockers Market (Million US$), 2019 - 2023
- Figure-10: Drug Class - Forecast for Beta-adrenergic Blockers Market (Million US$), 2024 - 2032
- Figure-11: Drug Class - Vasodilators Market (Million US$), 2019 - 2023
- Figure-12: Drug Class - Forecast for Vasodilators Market (Million US$), 2024 - 2032
- Figure-13: Drug Class - Angiotensin-converting Enzyme (ACE) Inhibitors Market (Million US$), 2019 - 2023
- Figure-14: Drug Class - Forecast for Angiotensin-converting Enzyme (ACE) Inhibitors Market (Million US$), 2024 - 2032
- Figure-15: Drug Class - Angiotensin-receptor Blockers Market (Million US$), 2019 - 2023
- Figure-16: Drug Class - Forecast for Angiotensin-receptor Blockers Market (Million US$), 2024 - 2032
- Figure-17: Drug Class - Analgesics Market (Million US$), 2019 - 2023
- Figure-18: Drug Class - Forecast for Analgesics Market (Million US$), 2024 - 2032
- Figure-19: Drug Class - Thrombolytics Market (Million US$), 2019 - 2023
- Figure-20: Drug Class - Forecast for Thrombolytics Market (Million US$), 2024 - 2032
- Figure-21: Distribution Channel - Hospitals Market (Million US$), 2019 - 2023
- Figure-22: Distribution Channel - Forecast for Hospitals Market (Million US$), 2024 - 2032
- Figure-23: Distribution Channel - Hospital Pharmacies Market (Million US$), 2019 - 2023
- Figure-24: Distribution Channel - Forecast for Hospital Pharmacies Market (Million US$), 2024 - 2032
- Figure-25: Distribution Channel - Drug Stores Market (Million US$), 2019 - 2023
- Figure-26: Distribution Channel - Forecast for Drug Stores Market (Million US$), 2024 - 2032
- Figure-27: Distribution Channel - Online Drug Stores Market (Million US$), 2019 - 2023
- Figure-28: Distribution Channel - Forecast for Online Drug Stores Market (Million US$), 2024 - 2032
- Figure-29: United States - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-30: United States - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-31: Canada - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-32: Canada - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-33: France - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-34: France - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-35: Germany - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-36: Germany - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-37: Italy - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-38: Italy - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-39: Spain - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-40: Spain - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-41: United Kingdom - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-42: United Kingdom - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-43: Belgium - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-44: Belgium - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-45: Netherlands - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-46: Netherlands - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-47: Turkey - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-48: Turkey - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-49: China - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-50: China - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-51: Japan - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-52: Japan - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-53: India - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-54: India - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-55: South Korea - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-56: South Korea - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-57: Thailand - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-58: Thailand - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-59: Malaysia - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-60: Malaysia - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-61: Indonesia - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-62: Indonesia - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-63: Australia - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-64: Australia - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-65: New Zealand - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-66: New Zealand - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-67: Brazil - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-68: Brazil - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-69: Mexico - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-70: Mexico - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-71: Argentina - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-72: Argentina - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-73: Saudi Arabia - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-74: Saudi Arabia - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-75: UAE - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-76: UAE - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-77: South Africa - Myocardial Infarction Market (Million US$), 2019 - 2023
- Figure-78: South Africa - Forecast for Myocardial Infarction Market (Million US$), 2024 - 2032
- Figure-79: Pfizer Inc. - Global Revenue Market (Million US$), 2019 - 2023
- Figure-80: Pfizer Inc. - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-81: Bristol-Myers Squibb Co - Global Revenue Market (Million US$), 2019 - 2023
- Figure-82: Bristol-Myers Squibb Co - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-83: AstraZeneca plc. - Global Revenue Market (Million US$), 2019 - 2023
- Figure-84: AstraZeneca plc. - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-85: Merck KGaA. - Global Revenue Market (Million US$), 2019 - 2023
- Figure-86: Merck KGaA. - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-87: Daiichi Sankyo Co Ltd - Global Revenue Market (Million US$), 2019 - 2023
- Figure-88: Daiichi Sankyo Co Ltd - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-89: Sanofi S.A. - Global Revenue Market (Million US$), 2019 - 2023
- Figure-90: Sanofi S.A. - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-91: Novartis International AG - Global Revenue Market (Million US$), 2019 - 2023
- Figure-92: Novartis International AG - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-93: Genentech - Global Revenue Market (Million US$), 2019 - 2023
- Figure-94: Genentech - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-95: Amgen - Global Revenue Market (Million US$), 2019 - 2023
- Figure-96: Amgen - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-97: Regeneron - Global Revenue Market (Million US$), 2019 - 2023
- Figure-98: Regeneron - Forecast for Global Revenue Market (Million US$), 2024 - 2032
- Figure-99: Takeda - Global Revenue Market (Million US$), 2019 - 2023
- Figure-100: Takeda - Forecast for Global Revenue Market (Million US$), 2024 - 2032
List of Tables
- Table-01: Global - Myocardial Infarction Market Share by Drug Class (Percent), 2019 - 2023
- Table-02: Global - Forecast for Myocardial Infarction Market Share by Drug Class (Percent), 2024 - 2032
- Table-03: Global - Myocardial Infarction Market Share by Distribution Channel (Percent), 2019 - 2023
- Table-04: Global - Forecast for Myocardial Infarction Market Share by Distribution Channel (Percent), 2024 - 2032
- Table-05: Global - Myocardial Infarction Market Share by Countries (Percent), 2019 - 2023
- Table-06: Global - Forecast for Myocardial Infarction Market Share by Countries (Percent), 2024 - 2032
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.